Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.

Peng, Qian; Yin, Yue; Liang, Min; Zhao, Mingye; Shao, Taihang; Tang, Yaqian; Mei, Zhiqing; Li, Hao; Tang, Wenxi

Peng, Qian; Yin, Yue; Liang, Min; Zhao, Mingye; Shao, Taihang; Tang, Yaqian; Mei, Zhiqing; Li, Hao; Tang, Wenxi.

Afiliación

Peng Q; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Yin Y; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Liang M; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Zhao M; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Shao T; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Tang Y; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Mei Z; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Li H; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Tang W; Department of Public Administration, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China. tokammy@cpu.edu.cn.

Cost Eff Resour Alloc ; 21(1): 80, 2023 Nov 02.

Article en En | MEDLINE | ID: mdl-37915053

Palabras clave

Advanced lung cancer; China; Cost-effectiveness threshold; QALY; Value; Willingness-to-pay

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cost Eff Resour Alloc Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google